Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

cts receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease, Traficet-EN is being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role. ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once-daily oral dosing. Traficet-EN may offer advantages
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Switzerland, September 15, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), a ... store adult stem cells, said today that revenues for the ... of $4.0 million for the same quarter a year ago. ... million. The Company recorded disposable revenues of $4.8 ...
Cached Medicine Technology:ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 2ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 3ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 4ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 5ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 6ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 7ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... 2014 (HealthDay News) -- Expert pilots process visual information ... they make better decisions during landings, a new study ... techniques for pilots to master, and 36 percent of ... occur during final approach and landing. Researchers monitored ... moderately experienced pilots while they were at the controls ...
(Date:12/15/2014)... December 15, 2014 At the leading, ... AutismOne and Focus Autism will ... with research on the effects of toxins to children’s ... intervention information. , Luminaries such as Dr. Lucija ... abroad with esteemed, credentialed colleagues of the United States ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , The inactivity or "silence" of certain genes ... leukemia as well as in response to treatment, according to ... specialists from the University Hospital of Navarra and the Center ... as well as the Reina Sofa Hospital in Cordoba, Andalusia. ...
... Company, the nation,s leading builder of healthcare facilities, has ... with the $42 million Phase Two expansion to the ... in March 2009 with completion scheduled for March 2011. ... emergency rooms, ICU, CCU, three operating rooms and 26 ...
... Link as SCHIP Legislation Signed Into LawWASHINGTON, Feb. ... voice for more than 36,000 frontline providers of ... commended President Barack Obama for singling out the ... signed an historic expansion of the State Children,s ...
... missed key DNA variant, researchers say , , FRIDAY, Feb. ... DNA called copy number variants may play a role ... findings support a sharp change of direction in genetics ... decades, researchers have identified dozens of genes and single ...
... ,History Shows Avalon Is No Champion of Corporate Governance,TUCSON, ... PRSC ) today commented on the recent ... Inc. (Pink Sheets: CITY) together with other related persons, ... sole director of Avalon, intends to initiate a consent ...
... Feb. 6 ev3 Inc. (Nasdaq: EVVV ) ... and its financial guidance for 2009 on Tuesday, Febuary 24, ... conference call and webcast the same day at 7:30 a.m. ... review its fourth quarter and full-year operating results and future ...
Cached Medicine News:Health News:New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 3Health News:Genome Study Points to New Culprit for Schizophrenia 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 3Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 4Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 5Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 6Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 7Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
For general purposes...
... BcMag Streptavidin magnetic beads are ... of biotinylated molecules such as ... from cell lysates or hybridization ... highly dispersed, it can also ...
Medicine Products: